Ginkgo Bioworks Holdings, Inc. (BMV:DNA)
Mexico · Delayed Price · Currency is MXN | Market Cap | 9.16B -18.6% |
| Revenue (ttm) | 2.31B -37.0% |
| Net Income | -5.08B |
| EPS | -86.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,048 |
| Open | 117.00 |
| Previous Close | 170.00 |
| Day's Range | 117.00 - 117.00 |
| 52-Week Range | 117.00 - 289.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engi... [Read more]
Financial Performance
In 2025, Ginkgo Bioworks Holdings's revenue was $170.16 million, a decrease of -25.06% compared to the previous year's $227.04 million. Losses were -$312.76 million, -42.83% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ginkgo Bioworks announces partnership with Lilly TuneLab
Ginkgo Bioworks (DNA) announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company…
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platf...
Ginkgo Bioworks awarded up to $17.5M subcontract under ARPA-H GIVE program
Ginkgo Bioworks (DNA) has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s Genetic Medicines and Individualized Manufacturing for Everyone program. ...
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health's (ARPA-H) Genetic M...
Ginkgo Bioworks downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Brendan Smith downgraded Ginkgo Bioworks (DNA) to Hold from Buy with a price target of $9, down from $12. The company reported another sales miss in Q2,…
Ginkgo Bioworks Holdings Earnings Call Transcript: Q2 2026
Revenue and cash burn declined year-over-year, reflecting restructuring and cost controls, while investment in autonomous labs and AI continues. Major new contracts with academic institutions and the launch of cost-competitive CRO services position the business for future growth.
Ginkgo Bioworks Holdings Earnings release: Q2 2026
Ginkgo Bioworks Holdings released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Ginkgo Bioworks Holdings Slides: Q2 2026
Ginkgo Bioworks Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Ginkgo Bioworks Holdings Quarterly report: Q2 2026
Ginkgo Bioworks Holdings has published its Q2 2026 quarterly earnings report on August 5, 2026.
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to mak...
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
16:38 EDT Ginkgo Bioworks (DNA) reaffirms 2026 expected total cash burn of ($150M)-($125M)
Ginkgo Bioworks Holdings Earnings Call Transcript: Q1 2026
Revenue and cash burn declined year-over-year as restructuring and the biosecurity spin-off took effect. The company is investing heavily in autonomous labs, with Nebula now exceeding 100 RACs and new partnerships expanding cloud-based lab services. Strong cash reserves support continued innovation.
Ginkgo Bioworks Holdings Earnings release: Q1 2026
Ginkgo Bioworks Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ginkgo Bioworks Holdings Quarterly report: Q1 2026
Ginkgo Bioworks Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Ginkgo Bioworks Holdings Slides: Q1 2026
Ginkgo Bioworks Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "G...
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026 BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plan...
Ginkgo Bioworks Holdings Proxy statement: Proxy filing
Ginkgo Bioworks Holdings filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Ginkgo Bioworks Holdings Proxy statement: Proxy filing
Ginkgo Bioworks Holdings filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Ginkgo Bioworks price target lowered to $5 from $9 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $5 from $9 and keeps a Sell rating on the shares. The company announced the divestiture…
Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure
BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo...
Ginkgo Bioworks expects total cash burn of ($150M)-($125M) in 2026
16:30 EST Ginkgo Bioworks (DNA) expects total cash burn of ($150M)-($125M) in 2026
Ginkgo Bioworks Holdings Earnings Call Transcript: Q4 2025
Restructuring and cost controls led to a 55% reduction in annual cash burn, with a strategic pivot to autonomous labs and divestiture of the biosecurity business. Major contract wins and AI collaborations highlight leadership in lab automation.
Ginkgo Bioworks Holdings Annual report: Q4 2025
Ginkgo Bioworks Holdings has published its Q4 2025 annual report on February 26, 2026.
Ginkgo Bioworks Holdings Earnings release: Q4 2025
Ginkgo Bioworks Holdings released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.